Before we go into details of Delcath Systems, Inc. (NASDAQ:DCTH), a biotech company that needs your immediate attention is OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP). OBMP is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer. While trading at mere $0.235, any positive data on its prostate cancer vaccine could potential send the share prices soaring. OncBioMune Pharmaceuticals, Inc. is headquartered in Baton Rouge, Louisiana. OBMP recently announced that the European Patent Office approved the Company’s patent application protecting ProscaVax as a PSA (prostate specific antigen) cancer vaccine. The patent is broad in scope covering an array of therapeutic cancer vaccine compositions built upon OncBioMune’s protein and antigen platform technology. The patent protects OncBioMune’s PSA cancer vaccine in 38 participating European Patent Organisation states.
Shares of Delcath Systems, Inc. (NASDAQ:DCTH) are currently down by -5.26% from the open today and are trading at $0.20. More than 13,601,426 shares have exchanged hands compared to an average trading volume of 2.56M. At the current pps, the market cap stands at $0.40M. The stock prices of Delcath Systems, Inc. (NASDAQ:DCTH) are currently trading at -99.82% below its 52 week high and 53.18% above its 52 week low.
Delcath Systems, Inc. (NASDAQ:DCTH) has been in the news for all the right reasons. Recently, Delcath Systems, Inc. (NASDAQ:DCTH) announced that it is all set to announce its earnings on Mar 20/b. As per Zack’s analyst ratings, Delcath Systems, Inc. (NASDAQ:DCTH) currently has an average brokerage rating of . On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:DCTH) is $ with a high of $ and a low of $.
Let’s take a look at the technical analysis.
The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend. The market is approaching oversold territory. Be watchful of a trend reversal.
The The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oid prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). .
The relative strength index (RSI) is a momentum osciallator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50).